Yes, subcutaneous rapid-acting insulin at 0.1 U/kg can effectively treat uncomplicated hyperglycemia without IV fluids, particularly in DKA settings.
For uncomplicated diabetic ketoacidosis (DKA), the 2025 ADA guidelines explicitly support subcutaneous rapid-acting insulin analog at 0.1 U/kg as an alternative to IV insulin infusion 1. This approach is specifically outlined in their DKA treatment algorithm for mild DKA cases.
Dosing Strategy
The recommended approach is:
- Initial dose: 0.1 U/kg subcutaneous rapid-acting insulin analog (lispro or aspart) as a bolus
- Maintenance: 0.1 U/kg every 1 hour OR 0.2 U/kg every 2 hours 1
- Continue until glucose reaches 150-200 mg/dL range for DKA resolution 1
Evidence Supporting This Approach
Multiple randomized trials demonstrate that subcutaneous rapid-acting insulin analogs are as effective as IV regular insulin for uncomplicated DKA:
- Time to DKA resolution: No significant difference between subcutaneous and IV routes (mean difference 0.2 hours, not statistically significant) 2
- Safety profile: Similar or lower hypoglycemia rates with subcutaneous administration 2, 3
- Pediatric data: Subcutaneous insulin aspart at 0.15 U/kg every 2 hours showed faster recovery and shorter hospital stays in children with moderate DKA 4
Critical Caveats
When This Approach Works:
- Uncomplicated DKA only (mild to moderate severity)
- Adequate peripheral perfusion (subcutaneous absorption requires good tissue perfusion)
- Patient can be monitored frequently (every 1-2 hours)
- Emergency department or step-down unit setting acceptable 1
When IV Insulin is Mandatory:
- Severe DKA with hemodynamic instability 1
- Severe hypovolemia requiring aggressive fluid resuscitation 1
- Cardiac compromise 1
- Any critically ill patient where absorption may be unpredictable
Practical Implementation
The 2025 ADA guidelines emphasize that adequate fluid replacement must still occur even with subcutaneous insulin 1. The key difference is you're not using IV insulin, but crystalloid fluids (0.9% NaCl) should still be administered at clinically appropriate rates to replace 50% of estimated fluid deficit in the first 8-12 hours 1.
Monitoring Requirements:
- Point-of-care glucose every 1-2 hours initially 1
- Electrolytes, renal function, venous pH every 2-4 hours until stable 1
- Potassium replacement as needed (maintain 4-5 mmol/L) 1
Cost and Resource Considerations
This approach offers significant advantages:
- Avoids ICU admission for uncomplicated cases 5, 6
- 39% cost reduction demonstrated in one study 6
- No need for insulin infusion pumps 5
- Can be managed in regular medical ward 4
Comparison to Non-DKA Hyperglycemia
For simple hyperglycemia without ketoacidosis, the 2021 Lancet guidelines recommend a basal-plus approach with lower doses (0.1-0.25 U/kg/day of basal insulin) plus correctional doses 7. The 0.1 U/kg bolus dosing is specifically validated for DKA scenarios, not routine hyperglycemia management.
Bottom line: The 0.1 U/kg subcutaneous rapid-acting insulin dose is guideline-supported for uncomplicated DKA, but you must still provide adequate IV fluid resuscitation and frequent monitoring—you're replacing the IV insulin infusion, not eliminating supportive care.